A	B	C
1	Main
2		Brand Name	BMS-790052
3		Indication	HCV
4		Mechanism	NS5A inhibitor
5		Clinical Trials
6			Phase IIa n=48 tx-naïve g1 HCV reported at EASL 2010
7			10mg QD/60mg QD RVR of 92%/83%. cEVR 83%/83% (42% placebo). eRVR 83%/75% (8% placebo).
8			PROVE RVR/EVR of 69-81% and 68%-80%.
9
10			Single-dose in HCV
11			1.8log, 3.2log and 3.3log up to 100mg